Janux Q2 2024 net loss $6.0M; cash $646.3M; receives $7.5M Merck milestone

Janux Therapeutics, Inc.

2024-Q2 EPS reported -$0.40 revenue$10,149,000

Net loss of $6.0M vs $17.5M in Q2 2023; improvement driven by $7.5M milestone payment from Merck.
Cash and investments $646.3M at June 30, 2024, up from $344.0M at Dec 31, 2023.
R&D expense flat at $14.9M; G&A expense $7.8M vs $6.9M in prior year.
Enrollment ongoing for JANX007 (PSMA) and JANX008 (EGFR) trials; JANX007 data update expected 2H 2024.
Appointed Eric Dobmeier and Natasha Hernday to Board of Directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.